Growth and adrenal responsiveness with budesonide in young asthmatics.
Inhaled corticosteroid therapy for asthma is used increasingly from a pre-school age. Current knowledge of adverse systemic effects, however, is based on treatment of older children. Eighteen asthmatic children aged 4.5-7.4 years who had taken budesonide by Nebuhaler in doses averaging 200-1100 micrograms m-2 day-1 during the previous year were studied. Height velocities calculated over this period were no different from those of the normal population. Neither the velocities nor a modest delay in bone ages were related to budesonide dose. Every child responded normally to tetracosactrin. These young asthmatic children do not show a greater susceptibility to systemic effects from an inhaled corticosteroid than older counterparts.